BIO MEMBERS ARE WORKING AROUND THE CLOCK TO FIND SOLUTIONS TO COMBAT CORONAVIRUS

KEY POINTS

Companies are using their own internal funds to conduct initial R&D (often through Proof of Concept or Phase 1) to see if their therapeutics and vaccines may be applicable to this emerging infectious disease.

BIO is working closely with our members to help connect them to private sector, government and non-governmental partners as needed.

Several companies have partnerships with the US government, Chinese government, the Coalition for Epidemic Preparedness Innovations (CEPI), and with other companies to get into clinical trials as soon as they can. Several companies already have therapeutics trials underway in China.

BIO members, both large and small, have stepped up to work on vaccines, therapeutics and diagnostics to combat the global COVID-19.

BIO MEMBERS WORKING ON VACCINES:

- Alnylam
- AnGes
- Arcturus Therapeutics
- CSL Behring
- Eli Lilly
- EpiVax
- GeoVax
- GSK
- iBio
- Inovio
- J&J
- Mallinckrodt
- Medicago
- Moderna
- Novavax
- Sanofi Pasteur
- Tonix Pharmaceuticals
- Vaxart

* As of 4/2/2020

BIO MEMBERS WORKING ON THERAPEUTICS:

- Alnylam
- Amgen
- Bellerophon
- Genentech
- Gilead
- Grifols
- J&J
- NanoViricides
- Pfizer
- Regeneron
- Roivant Sciences
- SAB Biotherapeutics
- Takeda
- Vir

* As of 4/2/2020

BIO MEMBERS WORKING ON DIAGNOSTICS/DEVICES:

- Grifols
- Roche
- SAB Biotherapeutics

* As of 4/2/2020

Find out what companies are doing to combat the COVID-19 at BIO.org/coronavirus.

Source: BioCentury; BIO Internal Data